代谢功能障碍相关的脂肪肝病 (MASLD)，以前称为非酒精性脂肪肝病 (NAFLD)，是一个日益严重的全球健康问题，对肿瘤发生具有重大影响。本综述综合了 MASLD 与癌症风险之间关联的现有证据，强调了其作为肝内和肝外恶性肿瘤风险因素的作用。 MASLD 越来越被认为是肝细胞癌 (HCC) 的主要原因，其发病率与代谢功能障碍的患病率同步上升。此外，MASLD 与各种胃肠道癌症的风险升高有关，包括结直肠癌、食道癌、胃癌和胰腺癌。除了消化道之外，有证据表明 MASLD 还可能导致其他癌症的风险增加，例如乳腺癌、前列腺癌、甲状腺癌、妇科癌、肾癌和肺癌。了解这些关联的潜在机制以及 MASLD 对癌症风险的影响对于制定有针对性的筛查和预防策略至关重要。版权所有 © 2024。由 Elsevier Inc. 出版。

Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant implications for oncogenesis. This review synthesizes current evidence on the association between MASLD and cancer risk, highlighting its role as a risk factor for both intrahepatic and extrahepatic malignancies. MASLD is increasingly recognized as a major cause of hepatocellular carcinoma (HCC), with its incidence rising in parallel with the prevalence of metabolic dysfunction. Furthermore, MASLD is associated with an elevated risk of various gastrointestinal cancers, including colorectal, esophageal, stomach, and pancreatic cancers. Beyond the digestive tract, evidence suggests that MASLD may also contribute to an increased risk of other cancers such as breast, prostate, thyroid, gynecological, renal and lung cancers. Understanding the mechanisms underlying these associations and the impact of MASLD on cancer risk is crucial for developing targeted screening and prevention strategies.Copyright © 2024. Published by Elsevier Inc.